Cross-contamination Risk Assessment using FMEA tool
Abstract
In pharmaceutical manufacturing facilities, products with different therapeutic properties and potencies are manufactured in shared spaces, which poses a potential risk for cross-contamination. During the manufacturing process, cross-contamination may occur due to the uncontrolled release of dust, gases/vapors, mix-ups with other materials, residues on equipment, and contamination from operator’s clothing. By implementing adequate facility design and manufacturing operations aligned with Quality Risk Management principles, the risk of cross-contamination can be controlled. If a shared facility is used for manufacturing pharmaceutical products, strategic controls for identifying and managing the risks of cross-contamination should be in place. This article provides a structured and systematic framework for the risk-based identification of the worst-case product and manufacturing process among the products manufactured in the solid oral facility, addressing the high risk of cross-contamination.
Keywords: Cross-contamination, Contamination, Risk Assessment, Formal risk assessment, Quality Risk Management (QRM), Failure Mode Effect Analysis (FMEA), Oral Solid Dosage (OSD), Worst case, Contamination Control Strategies (CCS)
Keywords:
Cross-contamination, Contamination, Risk Assessment, Formal risk assessment, Quality Risk Management (QRM), ailure Mode Effect Analysis (FMEA), Oral Solid Dosage (OSD), Worst case, Contamination Control Strategies (CCS)DOI
https://doi.org/10.22270/jddt.v14i9.6765References
2. New Product Introduction (Risk Evaluation) - Pharma Beginners (pharmabeginers.com)
3. Cross Contamination, Mix-Ups & Microbial Contamination - SOP in Pharma (pharmabeginers.com)
4. FMEA | Failure Mode and Effects Analysis | Quality-One
5. Global Harmonization Task Force. 2000. Implementation of risk management principles and activities within a Quality Management System.
6. ICH Expert Working Group, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2005. ICH Harmonised Tripartite Guideline: Quality Risk Management Q9.
7. U.S. Department of Health and Human Services, Food and Drug Administration. 2006. Guidance for Industry: Quality Systems Approach to Pharmaceutical CGMP Regulations.
8. U.S. Department of Health and Human Services, Food and Drug Administration. 2004. RiskBased Method for Prioritizing CGMP Inspections of Pharmaceutical Manufacturing Sites – A Pilot Risk Ranking Model.
Published
Abstract Display: 1110 
PDF Downloads: 600 PDF Downloads: 39 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.